Top

Published in:

01-01-2014 | Original Article

Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis

Authors: Y. Li, V. K. Rauniyar, W. F. Yin, B. Hu, S. Ouyang, B. Xiao, H. Yang

Published in: Neurological Sciences | Issue 1/2014

Abstract

This study aimed to observe the changes of IL-21/21R in peripheral blood of myasthenia gravis (MG) patients with glucocorticoid treatment and further clarify its role in pathogenesis of MG. 20 MG patients and 15 healthy controls were enrolled in this prospective study. Measurement of serum IL-21 concentration in healthy controls and MG patients before and after glucocorticoid treatment was done using ELISA, whereas expression of IL-21R mRNA was determined by RT-PCR. In addition, serum levels of specific anti-AChR-IgG and its subclasses IgG₁, IgG₂, IgG₃ were also determined by ELISA as follows: (1) serum IL-21 concentration in MG patients was higher before treatment 86.94 ± 14.47 (pg/ml) and decreased significantly after glucocorticoid treatment 35.84 ± 16.13 (pg/ml) (p < 0.05), (2) relative OD values of IL-21R mRNA expressed in PBMCs of MG patients was higher 0.137 ± 0.023 and significantly decreased after glucocorticoid treatment 0.114 ± 0.023 (p < 0.05), while it was 0.107 ± 0.025 in control group, (3) serum concentration of IL-21 showed positive correlation with specific serum anti-AchR-IgG₁ levels. The results indicate that the serum IL-21 decreases with glucocorticoid treatment and might be crucial in pathogenesis of mechanism of glucocorticoid treatment on MG patients.

Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116(11):2843–2854PubMedCentralPubMedCrossRef

Conti-Fine BM, Milani M, Wang W (2008) CD4⁺ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci 1132:193–209PubMedCrossRef

Parrish-Novak J, Dillon SR, Nelson A et al (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57–63PubMedCrossRef

Kim HP, Korn LL, Gamero AM et al (2005) Calcium-dependent activation of interleukin-21 gene expression in T cells. J Biol Chem 280:25291–25297PubMedCrossRef

Spolski R, Leonard WJ (2008) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26:57–79PubMedCrossRef

Ozaki K, Kikly K, Michalovich D et al (2000) Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 97:11439–11444PubMedCrossRef

Liu R, Bai Y, Vollmer TL et al (2008) IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol 211:14–24PubMedCrossRef

Vollmer TL, Liu R, Price M et al (2005) Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol 174(5):2696–2701PubMed

Kasahara TM, Teixeira B, Ferreira TB et al (2013) The ex vivo production of IL-6 and IL-21 by CD4(+) T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 33:179–189PubMedCrossRef

10.

Hohlfeld R, Toyka KV, Heininger K (1984) Autoimmune human T lymphocyte specific for acetylcholine receptor. Nature 310:244–246PubMedCrossRef

11.

Wang W, Milani M, Ostlie N et al (2007) C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 178(11):7072–7080PubMedCentralPubMed

12.

Yang H, Zhang Y, Wu M et al (2010) Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dendritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3 + regulatory T-cell profile. Inflamm Res 59(3):197–205PubMedCrossRef

13.

Masuda M, Matsumoto M, Tanaka S et al (2010) Clinical implication of peripheral CD4+ CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 225(1–2):123–131PubMedCrossRef

14.

Hu B, Tian X, Huang H et al (2010) Expression of IL-21 in the peripheral blood of myasthenia gravis patients and its correlation with anti-AChR-Ab class switch. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35(9):958–963 ChinesePubMed

15.

Furukawa Y, Yoshikawa H, Iwasa K et al (2008) Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J Neuroimmunol 195(1–2):108–115PubMedCrossRef

16.

Spolski R, Leonard WJ (2008) The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 20(3):295–301PubMedCentralPubMedCrossRef

17.

Ozaki K, Spolski R, Ettinger R et al (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173:5361–5371PubMed

18.

Vinuesa CG, Cook MC, Angelucci C et al (2005) A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435:452–458PubMedCrossRef

19.

Wang XF, Yuan SL, Jiang L et al (2007) Changes of serum BAFF and IL-21 levels in patients with systemic lupus erythematosus and their clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 23(11):1041–1042 ChinesePubMed

20.

Wong CK, Wong PT, Tam LS et al (2010) Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity. J Clin Immunol 30(1):45–52PubMedCrossRef

21.

Rasmussen TK, Andersen T, Hvid M et al (2010) Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol 37(10):2014–2020PubMedCrossRef

22.

Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475–490PubMedCentralPubMedCrossRef

23.

Coutinho AE, Chapman KE (2011) The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 335(1):2–13PubMedCentralPubMedCrossRef

24.

Spies CM, Gaber T, Hahne M et al (2010) Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4⁺ T-cells. Immunol Lett 131(1):24–32PubMedCrossRef

25.

Stary G, Klein I, Bauer W et al (2011) Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. J Immunol 186(1):103–112PubMedCrossRef

26.

Momcilović M, Miljković Z, Popadić D et al (2008) Methylprednisolone inhibits interleukin-17 and interferon-gamma expression by both naive and primed T cells. BMC Immunol 9:47PubMedCentralPubMedCrossRef

27.

Jüngel A, Distler JH, Kurowska-Stolarska M et al (2004) Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50(5):1468–1476PubMedCrossRef

Title: Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis
Authors: Y. Li
V. K. Rauniyar
W. F. Yin
B. Hu
S. Ouyang
B. Xiao
H. Yang
Publication date: 01-01-2014
Publisher: Springer Milan
Published in: Neurological Sciences / Issue 1/2014
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-013-1460-3

At a glance: The STEP trials

Springer Medicine

Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Arterial compression of nerve is the primary cause of trigeminal neuralgia

The MTHFR C677T polymorphism modifies age at onset in Parkinson’s disease

Rare cerebellar lesions in a carbon monoxide poisoning case

The heat is on: a case of hyperthermia-induced posterior reversible encephalopathy syndrome (PRES)

A case of diffuse large B-cell lymphoma with localized femoral nerve palsy

Functional recovery and alterations in the expression and localization of protein kinase C following voluntary exercise in rat with cerebral infarction